Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$0.93 +5.1%	$1.01	$0.73 ▼ $82.50	$5.07M	2.58	1.16 million shs	59,306 shs
GOVX GeoVax Labs	$0.57 +13.9%	$0.96	$0.43 ▼ $11.18	$9.11M	3.36	867,702 shs	2.51 million shs
MIRA MIRA Pharmaceuticals	$1.11 -3.5%	$1.25	$0.51 ▼ $5.01	$18.78M	1.72	2.35 million shs	1.16 million shs
NRSN NeuroSense Therapeutics	$2.09	$1.69	$0.51 ▼ $2.60	$28.56M	1.66	264,340 shs	192,951 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	-4.45%	+6.67%	-15.38%	-14.56%	-98.56%
GOVX GeoVax Labs	+4.60%	-41.99%	-55.16%	-48.23%	-82.06%
MIRA MIRA Pharmaceuticals	-2.13%	-4.96%	-17.86%	+38.55%	+96.68%
NRSN NeuroSense Therapeutics	+9.42%	+10.58%	+16.76%	+120.51%	+69.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNSP CNS Pharmaceuticals	1.6892 of 5 stars	3.3	2.0	2.1	0.0	0.6
GOVX GeoVax Labs	3.3323 of 5 stars	3.6	5.0	1.9	1.7	0.6
MIRA MIRA Pharmaceuticals	2.6243 of 5 stars	3.7	5.0	0.9	0.0	0.6
NRSN NeuroSense Therapeutics	1.7097 of 5 stars	3.5	3.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNSP CNS Pharmaceuticals	2.50	Moderate Buy	$25.00	2,591.07% Upside
GOVX GeoVax Labs	3.29	Buy	$11.10	1,840.90% Upside
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,161.26% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	569.86% Upside

Current Analyst Ratings Breakdown

Latest CNSP, MIRA, GOVX, and NRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/22/2025	CNSP CNS Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	$5.37 per share	N/A
GOVX GeoVax Labs	$3.95M	2.31	N/A	N/A	$0.48 per share	1.19
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNSP CNS Pharmaceuticals	-$14.86M	-$3,748.50	N/A	∞	N/A	N/A	-385.41%	-193.20%	8/13/2025 (Estimated)
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-341.08%	-272.93%	8/12/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	N/A

Latest CNSP, MIRA, GOVX, and NRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	N/A	N/A	N/A	$0.37 million	N/A
5/15/2025	Q1 2025	CNSP CNS Pharmaceuticals	N/A	-$1.58	N/A	-$1.58	N/A	N/A
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNSP CNS Pharmaceuticals	N/A	4.94	4.94
GOVX GeoVax Labs	N/A	3.62	3.62
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86
NRSN NeuroSense Therapeutics	N/A	2.21	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNSP CNS Pharmaceuticals	14.02%
GOVX GeoVax Labs	6.09%
MIRA MIRA Pharmaceuticals	35.16%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
CNSP CNS Pharmaceuticals	0.07%
GOVX GeoVax Labs	5.70%
MIRA MIRA Pharmaceuticals	6.65%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNSP CNS Pharmaceuticals	5	5.46 million	5.46 million	Not Optionable
GOVX GeoVax Labs	10	15.93 million	15.02 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	16.92 million	15.80 million	Not Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

CNSP, MIRA, GOVX, and NRSN Headlines

Recent News About These Companies

Neurosense Therapeutics Ltd News (NRSN) - Investing.com

July 2, 2025 | investing.com

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

June 26, 2025 | tipranks.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.comK

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.comA

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025 | businesswire.com

NeuroSense Advances PrimeC Commercialization in Canada

March 19, 2025 | tipranks.com

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025 | businesswire.com

Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

March 12, 2025 | techbullion.comT

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment

February 19, 2025 | tipranks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP, MIRA, GOVX, and NRSN Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

$0.93 +0.05 (+5.14%)

As of 12:55 PM Eastern

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

GeoVax Labs NASDAQ:GOVX

$0.57 +0.07 (+13.88%)

As of 12:57 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.11 -0.04 (-3.48%)

As of 12:57 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

NeuroSense Therapeutics NASDAQ:NRSN

$2.09 0.00 (0.00%)

As of 12:46 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time